genXone S.A.

GX1

PLGENXN00013

Pharmaceuticals

End-of-day quote Warsaw S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
5.92 ^PLN	-1.33%		-7.79%	+10.04%

02-12	GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-12	GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 13, 2022 at 01:20 pm

genXone S.A. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was PLN 7.32 million compared to PLN 5.33 million a year ago. Net income was PLN 1.92 million compared to PLN 2.05 million a year ago.

Latest news about genXone S.A.

GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-12	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-12	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/02/23	CI
GenXone S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	10/02/23	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
GenXone S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
GenXone S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	11/02/22	CI
GenXone S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
An unknown buyer acquired 14.3% stake in genXone S.A. from Torox Eko FIZAN, fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	06/06/21	CI
Genxone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	12/02/21	CI
GenXone S.A. has completed an IPO in the amount of PLN 7.3544 million.	25/08/20	CI
GenXone S.A. announced that it has received PLN 4.14 million in funding from INC S.A.	15/04/20	CI
GenXone Raises USD 1 Million in Private Placement	15/04/20	CI
Medcamp S.A. agreed additional 34% stake in genXone S.A from Torox Eko FIZAN fund managed by AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.	12/03/20	CI
GenXone S.A. has filed an IPO in the amount of PLN 4.002 million.	21/11/19	CI
Medcamp S.A. acquired 29.84% stake in GENXONE sp. z o.o. for PLN 0.39 million.	12/09/17	CI

Chart genXone S.A.

Duration

Period

More charts

Company Profile

Genxone SA is a Poland-based company, which specializes in NGS (next generation sequencing) and medical diagnostics. The Company is involved in the development and marketing of nanoforming technology in the field of science, business and medicine and cooperates as a commercial partner with Oxford Nanopore Technologies - biotechnological innovation entity.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
GENXONE S.A.	+10.04%	5.05M
MERCK KGAA	+16.93%	78.22B
KYOWA KIRIN CO. LTD.	+8.80%	8.84B
SK BIOPHARMACEUTICALS CO., LTD.	-14.24%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.95%	4.82B
YUHAN CORPORATION	+5.96%	4.2B
INDIVIOR PLC	+11.81%	2.28B
BETTA PHARMACEUTICALS CO., LTD.	-23.57%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+17.77%	2.2B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.28%	2.12B